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Abstract 
 
The big data revolution is making vast amounts of information available in all sectors of the economy 
including health care. One important type of data that is particularly relevant to medicine is observational 
data from actual practice. In comparison to experimental data from clinical studies, observational data 
offers much larger sample sizes and much broader coverage of patient variables. Properly combining 
observational data with experimental data can facilitate precision medicine by enabling detection of 
heterogeneity in patient responses to treatments and tailoring of health care to the specific needs of 
individuals. However, because it is high-dimensional and uncontrolled, observational data presents unique 
methodological challenges. The modeling and analysis tools of the production and operations 
management field are well-suited to these challenges and hence POM scholars are critical to the 
realization of precision medicine with its many benefits to society. 
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1.  Introduction 
 
Two parallel revolutions are about to transform the health care industry in profound ways. The first is in 
the practice of medicine, where imprecise one-size-fits-all medicine is being replaced by individually 
tailored precision medicine. The second is the analysis of data, where big data techniques are making it 
possible to extract patterns from vast amounts of digital information to guide decision making in a wide 
range of sectors and applications. Together these revolutions will fundamentally alter the clinical practice 
of medicine, by changing the way patients are diagnosed, treatments are selected, and care is delivered. 
But they will also have ramifications for the health care industry far beyond the practice of medicine, 
including the way patients choose and interact with providers, the way providers make strategic and 
tactical decisions, and the way payers reimburse and incentivize both patients and providers.  
 
The link between these two revolutions is data. The big data revolution is producing new ways to generate 
and analyze data and the precision medicine revolution is creating new ways to leverage it (see Kruse et 
al. (2016) for a broad review of the medical literature on using data in health care). In particular, big data 
methods are making it possible to go beyond experimental data generated by clinical studies and take 
advantage of observational data about patients in uncontrolled settings. Observational data can come from 
medical records, online reviews, mobile devices and many other sources. In contrast to experimental data, 
observational data is cheaper to obtain, has much larger sample sizes and addresses a much wider range of 
variables. For example, less than 5% of adult cancer patients are part of a clinical trial (Unger et al., 
2017).  Furthermore, since only patients meeting certain criteria can enroll in trials, patients with 
uncommon tumor types, older patients, and patients with a poor performance status or comorbidities are 
frequently underrepresented. As a result, researchers are increasingly looking to observational data to 
study cancer treatments and to identify side effects not apparent in randomized clinical trials (Spigel, 
2010).  By making virtually every act of health maintenance and patient treatment available for study, big 
data approaches are opening the possibility of true precision medicine that enables patients to receive care 
best matched to their specific health condition, individual characteristics and personal preferences. 
 
However, although observational data has enormous potential, it presents problems not present with 
experimental data. In clinical experiments subjects are selected to minimize bias and are organized into 
treatment and control groups, which makes for crisp statistical conclusions. In contrast, observational data 
comes from actual patient experiences and can therefore suffer from bias, censoring, insufficient sample 
size and other problems. Therefore, in order to use observational data to guide health care decisions we 
must find ways to correct for the inherent flaws in the data. This is where the emerging tools of analytics 
and machine learning come in, and where the POM field can play an important role in bringing about the 
merger of big data and precision medicine to revolutionize health care.  
 
In the following, we describe the path to precision medicine, the roles new types of data will play, the 
methodological challenges of collecting and using these data, and the stakeholder impacts and benefits 
that will ensue. We pay particular attention to research streams and opportunities where POM scholars are 
having, and can continue to have, a major impact on the big data/precision medicine revolution. 
 
2. Precision Medicine 
 
In stark contrast with one-size-fits-all medicine, in which disease treatment and prevention strategies are 
applied to everyone without regard to individual differences, precision medicine involves “the tailoring of 
medical treatment to the individual characteristics of each patient” (National Research Council, 2011). 
The Federal Drug Administration (2018) elaborated on this distinction with the following description: 
“Most medical treatments are designed for the "average patient" as a "one-size-fits-all-approach," which 
may be successful for some patients but not for others. Precision medicine, sometimes known as 
"personalized medicine", is an innovative approach to tailoring disease prevention and treatment by 
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taking into account differences in people's characteristics, environments, and lifestyles. The goal of 
precision medicine is to target the right treatments to the right patients at the right time.”  
 
Precision medicine, like all health care, involves two basic elements – decision making and execution. We 
must decide what to do, and then do it properly. Of course, execution of the various health care activities 
(tests, procedures, medications, etc.) is essential. But precision medicine is concerned primarily with 
selecting the right activities for a given patient, i.e., the decision-making facet of health care. Most 
discussions of precision medicine focus specifically on decisions made by a clinician regarding treatment 
(e.g., what drug/dosage to prescribe).  
 
But health care decisions involve much more than medical treatment and clinicians. As we depict in 
Figure 1, the health care process is usually initiated by a patient selecting a type of care. This could range 
from consulting a website for self-treatment information to deciding to see a medical specialist. Then the 
patient, possibly with assistance from a health care professional or influence from an insurance company, 
selects a provider. Again, there is a wide range of options, from engaging a fitness coach to selecting a 
surgeon. Finally, the provider, hopefully with strong input from the patient and probably with awareness 
of payer policies, implements some kind of care path. This could involve tests, medications, therapies or 
any number of other measures to address the patient’s needs. Frequently, because current health care is far 
from precision medicine, iteration is required. The patient may try multiple types of health care and 
engage multiple providers. The locus of decision making may shift between the patient, provider and 
payer, with the patient dominating type of health care decisions, providers dominating care path decisions 
and the payer influencing decisions across the spectrum. Whether or not the patient winds up satisfied 
with his/her health outcome depends on the combined impact of all these decisions, as well as the quality 
of execution within the care paths. 
 
 
 
 
Figure 1: Health Care Decisions.  
 
To achieve its full potential, precision medicine must address all of these levels of heath care decisions. It 
should help patients make good decisions about what type of care to seek. For example, a diabetic patient 
should be able to get information about what symptoms indicate he/she should seek diet advice on 
Dlife.com and what symptoms indicate a need for prompt medical intervention. Precision medicine 
should also help patients (and providers) choose the right provider for a particular patient. For example, a 
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patient in need of heart surgery, should have access to rankings or outcome data to help him/her (perhaps 
with help from his/her cardiologist) choose a surgeon. Finally, precision medicine should help all of the 
actors involved in implementing a care path make the best decisions about tests, procedures, dosages, and 
other aspects of the health care process.   
 
Although “precision medicine” has emerged as the most popular term for individually tailored health 
care, there are other terms in use. The older “personalized medicine” is regarded by many as 
interchangeable with personalized medicine, but by some as a literal call for individualized medicine (see 
National Research Council, 2011). Since, in some cases, the most effective treatment may not be 
individually tailored, these people argue (without excuse for the pun) that “precision medicine” is the 
more precise term. “Pharmacogenomics” is a specific instance of precision medicine, which makes use of 
genetic information to tailor pharmacological treatments to patients. Finally, an overlapping term is 
“evidence-based medicine” which refers to the use of relevant data to guide medical decisions. However, 
while precision medicine is always evidence-based, not all evidence-based medicine is personalized. As 
we describe in Wang et al. (2017), many research studies focus on the response of an average patient to a 
particular treatment, and therefore imply “one-size-fits-all” protocols.  
 
3.  The Role of Big Data in Precision Medicine 
 
Neither one-size-fits-all medicine, nor precision medicine, nor the stages in between them, are uniquely 
defined entities. Instead they represent a continuum of practices whose outcomes improve with the 
amount and type of data they leverage to guide decisions.  
 
The continuum of one-size-fits-all medicine ranges from a pure trial-and-error process, in which the 
patient (or physician) selects randomly from a set of treatments in hopes of achieving an improvement, to 
evidence-based priority rules, in which the patient (physician) tries alternatives in decreasing order of 
their probability of success. By using success rate data to rank order the alternatives, we can increase the 
likelihood and speed of achieving a good outcome. More accurate success rate data will produce a more 
efficient search process. However, regardless of whether success rates are raw or risk adjusted1, this type 
of data will lead to the same rank ordering of alternatives for all patients, and hence one-size-fits-all 
medicine. That is, all patients will start with the top-ranked option and work their way down the list in the 
same order. When patient responses to the various treatments are heterogeneous, this ensures inefficiency 
in the process, no matter how refined the success rate data.  
 
Precision medicine can also involve trial-and-error, but the treatment alternatives and/or likelihoods of 
success are tailored to the individual patient. The most basic form of precision medicine would be a 
treatment that is determined by a single individual characteristic (e.g., a dosage based on the precise 
weight of the patient). As precision medicine takes into account more patient descriptors, such as 
comorbidities, genetic markers, preferences, lifestyle attributes, etc., the alternative set and outcome 
likelihoods can be refined. One reason pharmacogenomics has received so much attention within the 
precision medicine literature is that scientists expect many new indicators of patient responses to drugs to 
be discovered at the genetic level.  
 
Between one-size-fits-all and precision medicine is stratified medicine, which divides patients into groups 
according to their response to a therapy. Since there may be other differences between patients in the 
                                                     
1 Risk-adjusted success rates correct for differences in patient characteristics by computing the average outcome 
from each alternative for a mix of patients that reflects the population. Note that the expected outcome for a 
“population average” patient may not reflect the outcome for any actual patient. Hence, as we note in Wang et al. 
(2017), population average data may not give appropriate rankings of alternatives when patient outcomes are 
heterogeneous.  
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same group, treatments will be rank ordered according to in-group success rates. Hence, we can think of 
this as “one-size-fits-some” medicine. An example of stratification is the classification of breast cancers 
into estrogen receptor (ER) positive and negative categories. ER positive cancers respond to hormone 
therapies, while ER negative cancers do not. Therefore, women in the two categories receive different 
chemotherapy protocols. Stratified medicine is also a continuum of practices because additional 
characteristics can be used to refine patient groupings. For example, breast cancers can also be classified 
as progesterone receptor (PR) positive or negative and as human epidermal growth factor receptor 2 
(HER2) positive or negative. Because patients in these categories respond differently to drugs, 
chemotherapy protocols can be better targeted by using the PR and HER2 biomarkers. When indicators 
get specific enough to divide patients into groups of one, stratified medicine becomes precision medicine.  
 
Figure 2 depicts the continuum from one-size-fits-all to precision medicine. For our purposes of linking 
the precision medicine revolution to the big data revolution, the most important aspect of this figure is the 
nature of the data analysis required to facilitate each type of medicine.  
 
 
Figure 2: Progression toward Precision Medicine. 
 
One-size-fits-all medicine requires population average effect analysis. The simplest form of such analysis 
is the frequentist approach, which uses outcomes to calculate the fraction of the population for which each 
alternative is effective. But when health outcomes cannot be measured in binary success/failure terms 
(e.g., liver transplant patients are evaluated in graft survival time, a continuous metric), a more 
sophisticated approach is required. In these circumstances, a risk-adjusted outcome analysis can be used 
to rank alternatives. For example, to compare the effectiveness of different hospitals in treating a 
particular cardiovascular disease, we can evaluate each hospital by dividing the outcome (e.g., five-year 
survival rate) by the expected outcome (i.e., the average five-year survival rate that would be achieved by 
the full population of hospitals if they treated the same mix of patients as the individual hospital). The 
expected outcome requires a regression across all patients and hospitals to compute (see Glance, et al., 
2006). The resulting observed-to-expected, or O/E, ratio provides a single number metric with which to 
rank providers. However, a single rank ordering based on O/E ratio is only appropriate when the relative 
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effectiveness of the providers does not depend on patient characteristics. When it does, rank order may be 
incorrect for some, or even all, patients. 
 
Stratified medicine uses heterogeneous effect analysis to correct for the failure of average effect analysis 
to account for patient differences. This requires patient characteristics along with outcomes. The more 
characteristics we can observe (e.g., age, gender, comorbidities, biomarkers, readings from wearable 
devices, etc.), the more likely we are to find characteristics that differentiate patients with regard to their 
responses. However, the more finely we stratify patients, the smaller our sample sizes become. In clinical 
studies, where data collection is expensive and difficult, it is often impossible to achieve large enough 
samples to permit subgroup analyses needed to detect heterogeneous patient responses.2 As we discuss 
below, finding the right balance between difference distinction and statistical significance is a key 
analytical challenge in implementing stratified medicine. 
 
Precision medicine uses personalized effect analysis, which often requires personalized data. Genome 
sequencing data is one form of personalized data. But so are preference (e.g., risk aversion) and lifestyle 
(e.g., diet and sleep) data. One could argue that all medicine makes use of at least some personalized data 
in the form of patient responses to provider inquiries (e.g., “How do you feel about the proposed course of 
action?). But precision medicine is aimed at a much more objective, evidence-based incorporation of 
personalized data than these traditional subjective assessments. Some of these data are being collected 
through traditional channels (e.g., doctor appointments) and compiled in electronic medical records 
(EMRs) or electronic health records (EHRs). But more detailed personalized data will require new 
approaches, such as mining social media or using handheld devices.   
 
A characteristic common to the data used for above analyses is multidimensionality. Because treatment 
alternatives are generally evaluated along multiple criteria, such as expected clinical outcome, risk of side 
effects, comfort and convenience of care, cost, and others, we need data with multiple dependent 
variables, as well as multiple independent variables, to support decision making. We can use big data to 
estimate the heterogeneity of patient responses along each dimension. But this will not be enough to 
facilitate patient treatment choices. We will also need some way to combine the results for the various 
dimensions. To do this at the personalized level, we will need individual preference data (in the form of 
linear weights or parameters for a nonlinear utility function). Furthermore, preferences on non-medical 
dimensions, such as travel distance, expense, familiarity, support services for family members, and many 
others, may be relevant to individual decisions. By combining heterogeneous outcome data and individual 
patient preference data we can achieve true precision medicine, in which choices are customized to the 
level of the individual patient.  
 
Ultimately, the progression from one-size-fits-all to precision medicine will be driven by more and better 
sources of data, and the analytics techniques needed to use them to guide health care decisions. But 
collecting and analyzing these data present a wide array of challenges, as we describe below.  
 
4.  Challenges in Collecting and Analyzing Big Data  
 
Precision medicine can make use of both experimental and observational data.  But, although challenges 
remain in the collection and use of experimental data to support health care decisions, these are familiar 
                                                     
2 For example, Park et al. (2015) compared percutaneous coronary intervention (PCI) using stents with coronary-
artery bypass grafting (CABG) in treating multi-vessel coronary artery disease. Although they found the rate of 
major adverse cardiovascular events was significantly higher among PCI patients than CABG patients, their ability 
to detect differences in outcomes among patient subgroups was limited by the size of the study. The study involved 
a total of 880 patients, which permitted analysis of only a small number of patient characteristics and restricted the 
statistical power of the analyses that were done.   
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problems clinical researchers have been dealing with for years. The new challenges presented by the 
incorporation of big data into health care decision making, and the ones most amenable to the skills of the 
POM community, are those associated with observational data. In this section, we first describe collection 
issues associated with this increasingly large-scale and personalized type of data. We then discuss 
estimation issues related to high dimensionality, bias, censoring and sample size issues that are common 
in uncontrolled observational data. Next, we highlight some modeling and optimization challenges that 
must be addressed to translate observational data into decision aids. Finally, because the ultimate goal is 
to enable all stakeholders in the health care system to make better decisions, we describe implementation 
challenges involved in presenting and disseminating information derived from big data analyses.  
 
4.1 Data Collection  
 
Health care observational data comes from many sources and in many formats. In this subsection, we 
describe common challenges that arise in the process of collecting large-scale observational data. These 
include technological barriers, incomplete or inaccurate data, privacy concerns and scientific challenges.  
 
4.1.1 Technological Barriers 
 
Advances in Information Technology (IT) have transformed health care data collection – from hand 
written notes, electronic health records, personal wearable devices, and many other sources. These 
advances also made it possible to capture both structured (e.g., administrative and claims data) and 
unstructured data (e.g., texts, images, audios, videos). While structured data are straightforward to 
analyze, and some text can be analyzed through textual analysis (see e.g., Wu, 2016), technology for 
converting medical images, audios and videos to textual or structured data that can be easily understood 
by non-medical researchers is still lacking.  As a result, for example, echocardiograms of mitral patients 
are routinely interpreted by a cardiologist or surgeon but are rarely are rarely available for use by a data 
analyst or policy maker.    
 
There is a lack of coordination of health IT implementation across different organizations or even in 
different departments of the same organization. Variations in data collection platforms and storage 
methods make it difficult to convert data from different sources into the same format for analysis. The 
lack of coordination across different organizations is a major barrier to health information exchange when 
a patient switches to a different health care provider or payer. For example, when a patient changes 
insurance company, a new enrollee ID is usually created. Duplicate IDs make it hard to link data from 
multiple insurance companies to the same patient.  
 
IT companies and researchers are continually seeking ways to translate complex and unstructured forms 
of information into usable data and hospitals and their IT providers are constantly working on better 
integration and interoperability.  But both of these have a great deal of room for improvement.  As a 
result, researchers seeking to use observational data to refine precision medicine must work with less-
than-ideal data sets and are likely to do so for some time.  But new research opportunities will continue to 
arise as these technological challenges are addressed. 
 
4.1.2 Incomplete or Inaccurate Data  
 
Missing values are common in observational data. These can occur due to unavailability of information 
(e.g., because a patient refused to disclose personal information or tests were not done), omissions by data 
administrators, accidental deletion, or data loss during merge and conversion. Missing values can be 
categorized broadly into three types: missing completely at random (i.e., independent of both the outcome 
variable and other independent variables), missing at random (i.e., independent of either the outcome 
variable or other independent variables), and missing not at random (i.e., correlated with the outcome 
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variable even after controlling for other independent variables). As we will discuss later, missing at 
random or completely at random may not be an important issue but missing not at random could cause 
biases in estimation. Techniques for dealing with missing value include imputation (i.e., replacing 
missing values with substituted values), deletion, interpolation and full analysis (see Little and Rubin 
(2014) for more details).  
 
Worse than missing values are inaccurate values. Inaccurate values can be the result of failure to 
understand terminology, over-reliance on manual input, inconsistent coding practice, or change of 
documentation policies. Compared with missing values, inaccurate values are much more difficult to 
detect, especially when they are not obviously outliers. One approach to identifying inaccurate values is 
to compare different data (e.g., claims, clinical and administrative data) for the same information. Another 
is to verify the raw data used to calculate the values. For example, one might check a patient’s height and 
weight if the patient’s body mass index has a suspicious value.    
 
4.1.3 Privacy Concerns 
 
Privacy is becoming an increasingly serious concern for patients as individual sensors have made it 
possible to monitor health at an increasingly detailed level. Users may be unwilling to share their 
personalized data with the providers of these devices or their clients. This could hinder prospects for 
collecting vast amounts of personalized data to be used in precision medicine as well as developing new 
and more accurate devices for health monitoring. Encryption and de-identification are traditional 
approaches to addressing privacy concerns. Medicalchain is a recently developed blockchain approach to 
protecting patient information such as those from EMRs while sharing data across medical providers and 
treatment sites (Azaria et al., 2016). 
 
Privacy is a concern to health care providers and payers, as well as to patients. Providers may be 
unwilling to share clinical data because there are laws and regulations that protect the privacy of patient 
information. They are also concerned that sharing a best practice with other providers may erode their 
competitive advantage in attracting patients. Payers may be unwilling to share their claims data because 
the data usually contain sensitive information about their cost structure and financial performance. 
Finally, providers and payers may be unwilling to share information with each other, because they do not 
want to lose negotiating power.  In theory, encryption and de-identification can be used to protect 
provider and payer data.  But doing this while enabling integration of data across participants and 
platforms is difficult.  Data science scholars (see, e.g., Li and Qin, 2017, Miller and Tucker, 2017) have 
proposed to use encryption and other means for protecting patient privacy when medical records are 
shared.    
 
4.1.4 Scientific Challenges 
 
Pharmacogenomics makes use of genetic information to predict patient responses to medication. Recent 
advances in genetic technology offer the prospect of being able to personalize medications to patients 
based on genetic tests.  However, while an increasing number of biomarkers have been discovered, their 
influence on outcomes is complex.  As a result, few biomarkers are currently used in clinical decision 
making or drug development and their ultimate utility is still a matter of debate.    
 
Several scientific challenges make it difficult to collect useful and accurate pharmacogenomics data. First, 
there are potentially many yet-to-be-identified genes and biomarkers that affect the pharmacology of a 
drug. Second, even for the identified pharmacogenomics biomarkers, some of the clinical results 
regarding the genetic association between the biomarker and the pharmacology of a drug have been 
inconsistent (Lam, 2013). Third, in addition to inherited genetic factors, many environmental, lifestyle 
and other factors could have important and complicated impacts on a patient’s response to a drug.  
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Researchers will continue to use clinical studies to link genetic and biomarker information to patient 
responses.  As such information becomes part of patient records, it will also become available for use as 
observational data in uncontrolled studies.   
 
4.2 Estimation  
 
Analyzing large-scale observational data presents several estimation issues, which can be grouped into 
those related to “high dimensionality” and those associated with the “uncontrolled” nature of the data. 
Further complicating analysis is that treatments may have heterogeneous effects on different patients, and 
that this heterogeneity may differ among treatments. In this subsection, we first discuss issues related to 
high dimensionality, and then issues caused by the uncontrolled nature of the data. Finally, we discuss the 
challenges of addressing these two types of issues simultaneously in treatment effect analysis. We shall 
note that the issues and potential solutions we point out below are by no means exhaustive. While they 
represent some key challenges, the area offers a great potential for many more research opportunities.  
 
4.2.1 High Dimensionality-Related Issues 
 
A direct challenge of working with a large number of variables is that it is unclear which variables are 
important and how they affect the response variable.  Finding the model, which could include nonlinear 
terms and interactions between variables, with the highest explanatory power is both computationally 
complex and statistically challenging. The most important statistical challenges are the issues of over-
fitting and multi-collinearity, and the problem of multiple testing.  
 
Over-fitting is a common problem in statistical analysis of high-dimensional data, especially when the 
number of observations is small relative to the number of variables. To illustrate this point, consider a 
simple example with two observations and one variable. It is possible to perfectly fit the data with a 
straight-line model that has R-squared equal to one and mean-squared error equal to zero.  As such, it has 
perfect in-sample performance, but will probably have very poor out-sample performance. If someone 
neglects the issue of over-fitting, he/she might erroneously pick such a model for prediction. Coefficient 
estimates and p-values in over-fitted models are misleading as well, as they often indicate that the effects 
of almost all variables are not statistically significant.   
 
Multi-collinearity refers to a situation where some independent variables are highly correlated. An 
increase in the number of variables increases the probability that some variables are multi-collinear. This 
is partly because some variables in observational data, though labeled differently, describe similar or 
closely related attributes (e.g., height and weight) or the same attribute measured at different times (e.g., 
blood pressure measured throughout the hospital stay). When some variables suffer from multi-
collinearity, the estimated effects of these variables will likely have large standard errors, which makes it 
appear that none of them is statistically relevant. 
 
A systematic approach to addressing both over-fitting and multi-collinearity issues is stepwise variable 
selection. Forward stepwise selection starts with a null model (i.e., no variable) and recursively adds the 
remaining variable that has the highest predictive power as measured by R-squared or residual sum of 
square. Inverse to this, backward stepwise selection starts with the full model (i.e., with all variables) and 
recursively removes one existing variable that has the lowest predictive power. These stepwise selection 
processes result in a series of candidate models, whose performances are then compared for model 
selection. Note, however, this sequential variable selection is often order dependent and computationally 
inefficient, especially when the number of candidate variables is large.  
 
A more sophisticated approach to addressing over-fitting and multi-collinearity is regularization, which 
introduces a regularization factor to penalize the number of independent variables that enter the model. 
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For example, the Least Absolute Shrinkage and Selection Operator (LASSO) is a widely used 
regularization method that penalizes the number of variables in a regression model and shrinks the 
coefficients of insignificant or small-impact variables towards zero (Bastani and Bayati, 2018, Bertsimas 
et al., 2016, Friedman et al., 2001). Under mild conditions, LASSO generates sparse models that identify 
the truly relevant variables. In contrast with stepwise variable selection, regularization methods can be 
applied even when the number of variables is larger than the number of observations. However, while 
methodologically intuitive, regularization methods raise several new questions, including: What is an 
appropriate amount of regularization? How to compare and select from different models that have similar 
explanatory powers?  
 
These questions can be answered with cross validation, a technique commonly used in the machine 
learning literature to compare the performance of different models (Friedman et al., 2001). It uses one set 
of data (called the “training sample” or “in-sample”) to train a model and an independent set of data 
(called the “testing sample” or “out-sample”) to test the model performance, which is usually measured 
by mean-squared error (MSE) and coverage rate. Cross validation selects a model with the right number 
and type of variables that best predict outcomes in the testing sample. However, because (1) different 
training and testing samples might result in different models and (2) there is a potential correlation 
between training and testing samples due to randomness, the model selection process is usually 
undertaken using multiple training and testing samples. A popular approach is k-fold cross validation, 
where the data is randomly divided into k parts. Each time, one of the k parts is held-out for testing and 
the remaining k-1 parts are used for training. Out-sample MSE of a model is calculated as the average of 
the k mean-squared errors.  
 
Besides cross validation, researchers have frequently used Akaike Information Criterion (AIC) and the 
Bayesian Information Criterion (BIC) for model selection as well. Both AIC and BIC balance the 
goodness-of-t of the model and its complexity, while BIC penalizes complexity more strongly than AIC 
and thus leads to sparser models. If the objective is to make better predictions, AIC and cross validations 
are commonly used. If the objective is to select variables that are truly economically relevant, BIC is 
typically preferred (Wang et al., 2007).  
 
Finally, multiple testing arises when one uses the same data to test a number of hypotheses. This issue is 
particularly common in health care settings, because multiple treatments are usually evaluated across 
multiple metrics for multiple patient groups at multiple providers. For purposes of illustration, suppose 
the treatment and control groups are patients who received mitral valve repair and replacement, 
respectively. To guide future treatment decisions, we want to know whether mitral valve repair is superior 
to replacement for some patients and whether the outcome differences between providers are 
heterogeneous across different patients. We could partition patients into groups based on their gender and 
compare repair with replacement as well as different providers for each group in terms of mortality, 
complication, readmission, graft failure, etc. The more quality metrics used for comparison, the more 
likely that the treatment and control groups differ on at least one quality metric due to random errors. 
Similarly, the more patient groups and providers we consider, the more likely that mitral valve repair will 
be found to be superior for at least one patient group at one provider.  
 
To address the issue of multiple testing, one needs to adjust the significance levels used for rejecting a 
null hypothesis. Bonferroni and Benjamini-Hochberg are two commonly used approaches partly due to 
their simplicity (see Bonferroni (1936), Benjamini and Hochberg (1995) for details). Note these tests rely 
on the assumption that different hypotheses are independent of each other, which might not be true in 
health care settings. For example, a patient who is more likely to have a complication is also more likely 
to have a readmission. A better and more complicated approach to finding adjusted significance levels is 
simulation. The null hypothesis is that the treatment does not have any effect on any observation for any 
metric. We can then randomly permute the treatment dummies among observations and test all 
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hypotheses to obtain a set of p values. After that, we repeat the permutation N times and count the number 
of times at least one test is deemed significant based on the target significance level a. The adjusted 
significance level can be calculated as a/N.  
 
4.2.2 Uncontrolled Data-Related Issues 
 
The uncontrolled nature of observational data introduces a number of challenges beyond those presented 
by the high-dimensionality of the data. In randomized controlled experiments, because observations are 
randomly assigned to treatment and control groups, we can control the number of observations in each 
group and the treatment effect can be estimated using the average outcome difference between the 
treatment and control groups. In observational studies, because we cannot randomly assign treatments to 
individuals, the treatment group may have systematically different attributes than the control group, 
which may result in estimation biases. The sample size of the treatment may also be insufficient to power 
the analysis, because unlike randomized experiments, the sample size of the treatment group in an 
observational study is not chosen by researchers for the purpose of detecting a given effect at the desired 
level of significance. In addition to bias and sample size issues, censoring is common in health care 
observational data, because an event (e.g., mortality) may occur beyond the data collection period. Below 
we first review a list of common sources of biases, which include omitted variable, sample selection and 
missing value, and then discuss issues of sample size and censored data.   
 
Omitted variable bias occurs because observational data may not include all variables of interest. While it 
is safe to omit a variable that is pure noise, omitting a variable that directly affects the outcome not only 
reduces the prediction accuracy of a model, but also creates biases in estimating the coefficients of all 
other variables that correlate with the omitted variable. For example, health-conscious patients may be 
more likely to seek treatments at a Center of Excellence (CoE). At the same time, these patients are 
healthier due to their lifestyles. However, we may not be able to observe from observational data whether 
a patient is health-conscious or not. Simply ignoring this unobservable variable will bias the estimate of 
the quality gap between CoEs and non-CoEs.  
 
Sample selection bias occurs when patients described by observational data are not a representative 
sample of the population of interest. For example, some transplant centers decide whether to admit a 
patient to their waiting lists based on the acuity of the patient. A very sick patient may be denied access to 
waiting lists. Therefore, comparing centers based on samples of admitted patients can lead to biased 
conclusions, especially when different centers have different patient admission practices. Similarly, 
selection bias is the primary threat to using observational data in comparative treatment analysis. For 
example, early-stage cancer patients with better prognoses are more likely to receive milder forms of 
chemotherapy with fewer side effects, while advanced-stage cancer patients with poorer prognoses are 
more likely to receive stronger drugs with harsher side effects.  Hence, both outcomes and side effects are 
strongly influenced by the mix of patients treated in a center.  Giordano et al. (2008) demonstrated how 
selection bias can lead to different or even opposite conclusions to those from randomized clinical trials in 
cancer research.  
 
Missing value bias is common in observational data that are collected over a long period of time and from 
different sources (e.g., multiple hospitals). If only a small portion of the values are missing, and the 
missing values happened completely at random, we can safely delete these observations without biasing 
the results. However, if values are missing in a systematic way or for a specific group of observations 
(e.g., patients with certain comorbidities), simply ignoring the observations will create estimation biases.  
 
Popular techniques for addressing these biases include instrumental variable, panel data, difference-in-
differences, regression discontinuity, selection models, and others. The instrumental variable (IV) method 
explores the variation of an exogenous variable that correlates with the endogenous variable but does not 
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directly correlate with the outcome variable. The IV approach extracts and uses only the exogenous 
variation of the variable of interest in the estimation, and obtains an unbiased estimate of its impact (see 
e.g., Bartel, Chan and Kim, 2016, Chan et al., 2016, Freeman et al., 2016, Ho et al., 2000, KC and 
Terwiesch, 2011, KC and Terwiesch, 2012, Kim et al., 2014, Lee et al., 2017, Lu et al., 2017, McClellan 
et al., 1994, Xu et al., 2017). For example, Hadley et al. (2010) showed that a properly chosen 
instrumental variable can correct the potential selection bias of observational data and provide consistent 
results as in randomized trials in the context of prostate cancer. Panel data models exploit longitudinal 
variations to take out unobserved time-invariant individual fixed effects (see e.g., Clark and Huckman, 
2012, Clark, Huckman and Staats, 2013, KC, 2013). The difference-in-differences method relies on the 
assumption that the treatment and control groups would have had parallel trends if there had been no 
treatment (see e.g., Song, Tucker and Murrell, 2015). It uses group fixed effects to capture time-invariant 
differences between the two groups and time fixed effects to capture the trends. Regression discontinuity 
exploits sharp changes in the variable of interest and compares outcomes of observations lying slightly 
above and below the threshold (see e.g., KC, 2018). Other techniques involve direct modeling of the bias 
generating process. For example, the Heckman Two-Stage selection model (see Heckman (1976, 1977) 
for more details) corrects for biases caused by sample selection or non-random missing data. Which 
technique is most appropriate depends on the context and the availability of exogenous variables. 
 
Even with big observational data, insufficient sample size may still be an issue, particularly as the 
stratifications in stratified medicine become finer.  In experimental studies, researchers use power 
analysis to determine the sample size required to detect a certain treatment effect at a given significance 
level, sample size is a critical part of the experiment design. However, in observational studies, because 
researchers have no control over the number of patients who receive a given treatment, the treatment 
group may have a very small number of observations, which creates estimation difficulties. For example, 
suppose we want to compare the mortality rates of two hospitals for a particular surgical procedure.  One 
hospital treated 200 patients with 4 deaths and the other hospital treated 10 patients with no deaths. Which 
hospital is better? Obviously, the second hospital has a lower mortality rate, but we cannot conclude that 
it is better because the small sample size makes it likely that this rate was largely due to randomness.  
 
The sample size issue described above is usually difficult to address without borrowing additional 
information from other sources. If we can construct a prior distribution regarding the outcome based on 
outside information, an empirical Bayes method can be used to estimate the effect of a treatment or 
compare multiple treatments. In the surgical example described above, such a prior could be the overall 
distribution of mortality rates across all hospitals, the relationship between a hospital’s volume and its 
outcome, or the correlations between outcomes of similar procedures. Dimick et al. (2009) applied the 
empirical Bayes method that first estimates the effects of volume on outcomes from the data and then 
uses updates based on actual performance to predict performance of a specific hospital. Similar ideas 
might be suited to analyzing the effectiveness of more advanced chemotherapy treatment for patients of 
uncommon cancer types with a given chromosome gain or loss (e.g., a Wilms tumor patient with 16q 
chromosome loss). For example, one could construct a prior using data from patients of similar cancer 
types with the same chromosome change (e.g., all other kidney cancer patients with 16q loss) and then 
use the Bayes method to update this prior specifically for Wilms tumor patients. 
 
Finally, censoring refers to the coding of a continuous variable into one number when the variable is 
larger or smaller than a specific value. There are three types of censoring: left censoring, interval 
censoring and right censoring, which correspond to different positions of the censored value. Right 
censoring is the most common in survival analysis, as an event of interest might happen beyond the study 
period. For example, suppose we use survival time as a quality metric to compare different hospitals for 
liver transplant surgery. The study period is all the years when data were collected, and the variable of 
interest is length of survival after transplant. However, we can only observe how long a patient survived 
only if the patient died before the last date of data collection.  
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One approach for dealing with censored data is to convert the variable of interest into binary indicators. 
For example, instead of analyzing how long a patient survived, we could analyze whether a patient 
survived more than one year after the transplant. However, the choice of the cut-off points may be 
arbitrary (e.g., one month vs. one year). Moreover, it usually fails to capture the long-term effect of the 
treatment. Another approach is survival analysis, which explicitly models survival time as a continuous 
outcome variable. Parametric survival analysis assumes that the underlying distribution of survival time 
follows a certain known distribution (e.g., exponential) whereas nonparametric survival analysis such as 
the Kaplan Meier method (see Wooldridge (2010) for more details) focuses on calculating and graphing 
survival probability as a function of time. A popular method for survival analysis is the Cox proportional 
hazards model, which is a semiparametric model that can be used to compare the survival time of two or 
more patient groups of interest.  
 
4.2.3 Issues Related to Treatment Effect Analysis 
 
To use big observational data to inform health care decisions we must simultaneously address issues 
related to both high-dimensionality and uncontrolled data in the context of treatment effect analysis.  
Estimating treatment effects is a different objective from predicting outcomes. Even though a more 
precise estimate of the treatment effect will improve the accuracy of outcome prediction, the model with 
the most predictive power does not necessarily capture the true treatment effect unbiasedly.  
 
Classic machine learning methods referenced above are proven to be effective for predicting outcomes 
while addressing the high-dimensionality challenge.  By themselves, these techniques are helpful in 
answering questions such as: How long will a patient with newly diagnosed stage III breast cancer 
survive? What is the probability that a patient with hypertension (pre-existing) may experience a major 
complication after a mitral valve surgery? Outcome prediction is particularly useful if a patient has 
already decided which health care path to follow or which treatment to receive. However, it is not directly 
useful for a patient who is trying to choose among alternative treatments, unless the causal effects of the 
treatments have been properly estimated.  For example, a patient may ask questions like: How is my 
quality of life likely to differ if I receive a kidney transplant instead of continuing renal dialysis?  What 
are the relative risks of complications if I choose to get a stent instead of a bypass graft?   
 
While the effect of a treatment can be calculated by comparing predicted outcomes with and without the 
treatment, the results may be statistically misleading for two reasons. First, the best model for outcome 
prediction may not be the best for treatment effect estimation. For example, if age is an important factor 
affecting survival and race is an important factor affecting the effectiveness of a treatment, a model 
focusing outcome prediction will include age as a key predictor whereas a model focusing on treatment 
effect estimation will instead include race as a key predictor. Second, there may be endogeneity issues, 
which can bias the estimate of treatment effects. Because patients are not randomly assigned to 
observations, the treatment and control groups may have systematic differences (such as those cause 
treatment selections) that affect their outcomes. As a result, the effect estimated from a simple subtraction 
includes not only the true treatment effect but also the systematic difference between the treatment and 
control groups.  
 
To modify classic machine learning methods for treatment effect analysis, we need to address two main 
issues. First, because we do not directly observe the treatment effect from data, we cannot use them as a 
dependent variable to train a model. If we instead use outcomes to train a model, an important variable 
that affects treatment effect but not outcome may be excluded during variable selection, whereas a less 
important variable that affects outcome but not treatment effect may be included in the final model. 
Second, because we do not know the treatment effects for observations in the testing sample, we cannot 
analyze the performance of a model by calculating its mean squared error or coverage rate or use cross 
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validation for model selection. If we use outcomes in cross validation, we are likely to choose a model 
with the best outcome instead of the best treatment effect prediction.  
 
One approach to addressing these issues is to use different penalization factors in LASSO to differentiate 
variables that affect outcomes from those that affect treatment effects (Imai and Ratkovic, 2013). This 
approach allows for the possibility that some variables have a relatively small impact on outcomes but a 
large impact on treatment effects. This approach, however, requires institutional knowledge to distinguish 
between the two types of variables. An alternative approach first transforms the original outcomes and 
then applies the standard LASSO with the transformed outcomes and original independent variables for 
treatment effect analyses (Signovitch, 2007).  
 
These approaches identify variables that significantly affect treatment effects when there are no pressing 
concerns of endogeneity. To address potential endogeneity issues associated with observational data, we 
need to integrate econometric methods such as the instrumental variable into machine learning models to 
obtain unbiased estimates of the treatment effects. For example, Li et al. (2017) combined LASSO and 
the instrumental variable technique to identify price competition in high-dimensional space. Approaches 
like this offer the best of both worlds by using machine learning to deal with big data and econometrics to 
establish causality. 
 
Existing studies that analyze the causal effect of a treatment have focused on the average treatment effect. 
These studies implicitly assume that a treatment has the same effect for all observations. However, it is 
possible that the same treatment has a positive effect on some patients but a negative or no effect on 
others. In cases when a treatment has a positive (or negative) effect on all patients, it is possible that the 
magnitude of the effect differs by patient. Recognizing the differences in patients’ responses to the same 
treatment, researchers have called for stratified medicine that identifies patient groups with heterogeneous 
treatment effects.  
 
One approach to identifying patient groups is to first interact the treatment dummy with patient 
characteristics and then include both the interaction terms and other variables in a regression model such 
as LASSO for variable selection. The main difficulty with this approach is that the number of interaction 
terms increases exponentially with the number of variables. As a result, this approach is computationally 
expensive and requires a large number of instruments (or other econometric techniques) to obtain 
unbiased estimates of all interaction terms. 
 
An alternative approach is to partition observations into groups for subgroup analyses. The first challenge 
with this approach is that the number of ways to partition patients increases exponentially with the 
number of patient characteristics. It is not clear how many patient groups we should have and which 
characteristics should be used for partitioning. The second challenge is that there is a clear tradeoff 
between relevance and reliability. A finer partitioning of patients provides more relevant information but 
may not have enough statistical power due to a reduced sample size.  A coarser partitioning of patients 
will have a larger sample size, but the information provided may not be as relevant.  
 
These challenges can be addressed by tree-based methods, which are data-driven automatic processes that 
partition observations into groups such that observations in the same group have similar treatment effects 
and those across different groups have different treatment effects. A tree method usually starts at the root 
where all observations are in the same group (called “parent” node) and recursively partitions 
observations into “child” nodes using the variable that increases in-sample goodness of fit the most. It 
then treats each child node as a parent node and continues the partitioning until a stopping criterion is 
reached. Finally, it uses cross validation to select the tree that has the best out-sample performance.  
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While it is straightforward to calculate the treatment effect for a group in randomized controlled trials 
using average outcome differences between the treatment and control groups (Athey and Imbens, 2016), 
we need to address potential endogeneity issues with observational data and use the instrumental variable 
or another econometric method to obtain unbiased estimates of treatment effects.  Furthermore, most 
existing tree-based methods are myopic in partitioning observations and may not achieve the best overall 
prediction accuracy. Dimitris et al. (2017) proposed an optimal tree to address this issue, but this 
approach is computationally expensive if the dimension of the problem is high.  
 
Finally, the main challenge of using big observational data to inform medical decisions at the individual 
patient level is that we cannot observe both the treatment and no-treatment conditions for a patient and no 
two patients are exactly alike. Even if we are able to perfectly match two patients based on observable 
characteristics, there is no guarantee that the two patients have the same unobservable characteristics. To 
address this main challenge and move practice closer to precision medicine, we can look to the inevitable 
increase in the amount of health care data and rise of real-time monitoring through use of wearable 
devices. In many health care settings, it is reasonable to assume that only a finite number of variables 
affect treatment effects, which means an increase in the number of observations will enable us to partition 
patients into finer groups without losing statistical power.  Real-time monitoring by wearable devices 
allows us to collect observations for the same patient on a daily or even hourly basis. If a treatment is 
assigned to the same patient at random times or based on observable variables, these observations 
constitute trials for the same patient (see e.g., Klasnja et al., 2015). For example, a wearable device might 
remind the wearer to take deep breaths as an anxiety reducing therapy (see e.g., Sarker et al., 2017). With 
some randomization of the reminders and measurement of the physical responses, the device could 
optimize a breathing strategy for a given individual (see e.g., Walton et al., 2018).  Finally, if the 
previously mentioned privacy concerns can be addressed, data from such devices could be pooled and 
used to determine the individual characteristics that make people most and least receptive to breathing 
therapy.    
 
In summary, heterogenous treatment analysis with high-dimensional observational data offers a wealth of 
research opportunities. New research in this area is emerging (see, e.g., Athey et al., 2017, Wang, Li and 
Hopp, 2017a & 2017b, Boruvka et al., 2017) and has the potential to sharpen precision medicine 
protocols for a vast range of patients. 
 
4.3 Modeling and Optimization  
 
Once we have used big data to estimate patient responses to various health care alternatives, the problem 
becomes how to use the results to facilitate better decisions across the health care system. These decisions 
include choice of type of health care and specific providers by patients, selection of specific treatments by 
patients and providers, strategic positioning and process improvement decisions by providers, 
reimbursement and incentive structure decisions by payers, and many others. We list some important 
decisions that present challenges amenable to the modeling and optimization skills of OM scholars below. 
 
4.3.1 Individual Patient Level 
 
In decentralized health care systems where patients can choose the type of treatment and the specific 
providers for the treatment, observational data can be used to understand how patients make choices and 
identify barriers that prevent patients from finding health care most suitable for them. When choosing a 
health care provider, patients consider not only outcome differences between providers but also travel 
distance, waiting time, insurance co-pay, etc. Patient choice models help understand not only the relative 
weights patients place on different factors but also how much outcomes would improve if one or more 
barriers are removed. For example, Wang et al. (2015) studied the impact of quality information, travel 
distance and insurance on patients’ choice of cardiac surgeons for mitral valve surgeries and found that 
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lack of quality information is the most important barrier preventing mitral patients from choosing the best 
care and reducing this barrier could improve mitral valve repair rate by 13%.  
 
Although choice models using observational data can help understand what patients are doing, analytical 
models using OM techniques such as optimization are needed to tell patients and their providers what 
they should do. Compared with traditional models that rely on wide range of assumptions, data-driven 
analytical models estimate parameters based on observational data and use them as input for modeling 
and optimization. One application of data-driven analytical models is multi-criteria decision making, 
where multiple treatments (e.g., surgery, stents and statins for carotid disease) are available and a patient 
needs to consider multiple factors (e.g., recovery time from treatment, risk of complications and life 
expectancy) in choosing a treatment. Multi-criteria decision making is challenging because a given 
treatment may look better on one criterion but worse on others.  OM techniques such as multi-objective 
optimization and the analytical network/hierarchical approach (Saaty, 2013) can help patients choose the 
best treatment based on their individual preferences. These techniques can also help patients with 
sensitivity analyses that help them see how their choice depends on outcome estimates and/or their 
personal preferences.    
 
In addition to multiple criteria, health care decisions often involve multiple periods.   For example, 
patients with chronic diseases are typically faced with a series of decisions to manage their condition.  In 
some cases, such decisions are spread over time because treatment options change over time. For 
example, patients waiting for an organ transplant must decide whether to accept a currently available 
organ or to wait for a future and potentially better organ.  Metastatic cancer patients can face similar 
decisions involving uncertain future options as they wait for improved chemotherapy options to become 
available.  This type of multi-period decision making is challenging, because a patient’s health status 
evolves over time. In the case of organ transplant, if a patient decides to reject an organ and stay on the 
waiting list, he/she might get a better offer in the future, but his/her health state might get worse. 
Problems like these can be addressed using familiar methods, such as linear programming and dynamic 
programming (Alagoz et al., 2009), but may also require new data analytics methods to update evolving 
options, risks, and patient characteristics to properly parameterize the models. 
 
4.3.2 Health Care System Level 
 
As data becomes more and more transparent, health care providers of all kinds will be faced with 
decisions of what services to offer. If patients can see which providers are substandard for which 
procedures, they will be able to selectively avoid them.  Since hospitals will no longer be able to use the 
halo from their strengths to hide their weaknesses, it will become increasingly difficult to offer a full 
range of medical services.  This will present hospitals and other medical providers with “invest or 
specialize” scenarios. They will either need to invest in process improvement to make their weakest 
services competitive or eliminate those services and compete on their strong services. Such decisions will 
be complicated by the fact that there are synergies between services (e.g., a strong transplant program for 
one type of organ may offer infrastructure and marketing advantages with which to build a transplant 
program for another type of organ). These complex strategic planning problems will require modeling 
support, which will need grounding in the types of data-driven evaluation of performance we have 
discussed in this paper. 
 
Observational data can also help health systems improve outcomes through better matching of patients to 
facility and/or provider.  As described earlier, the effect of a treatment may be heterogeneous for different 
patients and such heterogeneity may differ across treatments.  Here, the “treatment” could be the actual 
medical treatment (e.g., surgery, stent, statin), but it could also be the type of facility (e.g., doctor’s office, 
urgent care clinic, community hospital, research hospital) or the individual provider (e.g., specific 
surgeon).   Heterogeneous outcomes imply that a given facility or provider may be better suited to one 
17 
 
type of patient than another and that the “best” facility or provider will be different for different patients.  
Using big data analysis to uncover such heterogeneity in outcomes can enable health systems to better 
guide patients (e.g., through physician referrals) to the types and sources of care that best meet their 
individual needs.  By taking into account both clinical quality and operational efficiency, improvements 
in the matching process can help systems provide better health at a lower cost.   
 
Modeling and optimization can also help health systems respond to pay-for-performance systems. 
Increased transparency of hospital performance data, made possible by more sophisticated big data 
analytics, will allow payers such as CMS to tie reimbursements more closely to the actual value hospitals 
provide to patients.  An example of early efforts to do this are the hospital readmission reduction program 
(HRRP), which penalizes hospitals with excessive 30-day readmission rates and the hospital acquired 
condition reduction program (HACRP), which penalizes the worst quartile of hospitals with regard to 
hospital acquired infections.  Because these programs base penalties on coarse evaluations of under-
performing hospitals, they create incentives that may not align with the goal of promoting improvements 
in hospital performance.  For example, Zhang et al. (2016) developed a game-theoretic model that 
captures the competition among hospitals induced by HRRP’s benchmarking mechanism and found that 
low-performing hospitals prefer paying penalties to reducing readmissions.  Better performance 
evaluation will create opportunities for more targeted and more effective pay-for-performance 
mechanisms, which will require modeling and optimization support to exploit.   
 
4.3.3 Societal Level  
 
If a health care system were governed by a central planner who decides how to allocate limited treatment 
resources to different patients, heterogeneous and personalized data could be used directly to make better 
patient assignment decisions. But even this highly simplified version of the health care resource allocation 
problem is not entirely straightforward.  While it is generally simple to solve an allocation problem in 
which both treatment effects and disease states are deterministic, the problem becomes much harder if we 
consider uncertainty in the effect of a treatment and the progression of a disease. To illustrate this point, 
consider two treatment types (Treatment 1 and 2) and two disease states (State 1 and 2). Treatment 1 is 
more effective and expensive than Treatment 2, but none of the treatments can cure the disease.  
Furthermore, the disease state evolves over time as a function of prior state and treatment type. Because 
budget is limited in each period, the central planner must decide which patients to treat and the type of 
treatments to provide. This type of problem can be formulated using linear programming or dynamic 
program but is generally difficult to solve when the number of periods, treatment types or disease states 
under consideration is large. Zayas-Caban et al. (2017) proposed an asymptotically optimal heuristic 
based on a linear programming relaxation to the original stochastic formulation.    
 
Since no country or health care system operates in pure central planning mode, analyses of such systems 
are used as guides for narrow decisions that do involve central planning, such as which procedures should 
be covered in medical plans, which patients should be prioritized in allocating scarce resources, and what 
guidelines and regulations should be adopted.  Specific examples include allocating organs for transplant 
(Ata, Freidewald, Randa 2017), optimizing colonoscopy screening for colorectal cancer prevention and 
surveillance (Erenay, Alagoz, Said 2014)), allocating scarce healthcare resources in developing countries 
(Griffin, Keskinocak, Swann 2013), optimizing breast screening policies given heterogeneous adherence 
(Turgay et al. 2016). 
 
All real-world health systems are at least partially decentralized because patients have at least some 
choice about what treatment to get and where to get it.  Such systems still require modeling and 
optimization to design and plan. For example, to help system managers evaluate the value of a new type 
of information (e.g., EMR information made possible by Medicalchain), we need to be able to predict 
how the new information will affect patient decision making and how this will impact patients and other 
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stakeholders. An example of such a model is that of Wang et al. (2017), which analyzed the relative value 
of population-average and patient-specific quality information about cardiac surgeons.  This involved 
modeling patient choice of surgeon as a function of outcome quality, travel distance and waiting time on 
the surgical schedule and combining this with a queueing model to estimate patient waiting time. The 
results suggested that societal benefits (i.e., sum of patient utility) from using patient-specific information 
about mitral valve surgery outcomes are comparable to those achievable by enabling the best surgeons to 
treat 10%-20% more patients under population-average information. Analyses like these can help identify 
areas where more detailed information can facilitate precision medicine to achieve the greatest societal 
benefits.  
 
Modeling and optimization can also help understand and improve interactions between system managers 
and patients that govern how resources are used.  For example, in organ transplant systems, UNOS plays 
the role of system manager responsible for organ allocation. When an organ becomes available, patients 
with compatible blood type and antibody-antigen are sequenced according to their sickness, waiting time, 
proximity to donor, etc. The organ is then offered to patients in this sequence. UNOS quickly realized that 
patients who were more likely to receive an allocation were also more likely to reject the allocation. 
Hence, by using historical data to understand patients’ decisions, UNOS developed the Liver Simulation 
Allocation Model to compare potential outcomes of alternative allocation policies. Several studies have 
made use of this simulation to incorporate patient choice into optimization models that improve the 
allocation process (Su and Zenios, 2004, 2005 & 2006, Akan et al, 2012).  As more performance data 
becomes available as a result of the combined big data and precision medicine revolutions, analogous 
analyses of other scarce resources (e.g., elite surgeon time, experimental drugs, new imaging 
technologies, etc.) will become possible.  POM scholars are well-equipped to provide the needed analytic 
innovations. 
 
4.4 Implementation  
 
Achieving precision medicine, as we have described it here, will require more than solving statistical and 
analytics problems or creating simulation and optimization models. We must also find ways to 
communicate complex information about treatment options and outcomes to patients and providers in 
ways they can use it. This will require better displays (e.g., customized rankings in web pages) and tools 
for dealing with multi-criteria decisions (e.g., aids to help users figure out weights for criteria or 
mechanisms for using partial weight information to choose between alternatives).  
 
A number of observers have noted that public reporting of health care outcomes has been less effective 
than anticipated in altering patient and provider behavior (see e.g., DeVore et al. 2012, Ryan et al. 2012 
and Smith et al. 2012).  Saghafian and Hopp (2018) concluded that the primary reason for this is that 
patients have acted as though they either do not have or do not understand the publically reported data. 
This implies that information contained in this data has not been communicated in a clear and usable way.  
If this is indeed the case, then there is considerable opportunity to advance progress toward precision 
medicine by better communicating the information being generated by the big data revolution.  POM 
scholars can contribute to research into how patients perceive information about uncertain outcomes, how 
trust (e.g., of doctors, insurance companies, government) influences patient reception of information from 
various sources, and many other practical questions related to the use of information in real-world 
settings.   
 
However, having and understanding the data needed to make effective decisions for precision health care 
is not enough.  Both patients and providers must act upon it.  If other factors distort treatment decisions, 
patient and societal benefits will fall short of their potential.  Three issues that may prevent a provider 
from acting in patients’ best interests are: (1) Some hospitals are profit-driven, so they may pick patients 
or prescribe medications based on how much revenue they could generate rather than how well the 
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patients could be treated; (2) Hospitals that are rated and reimbursed according to imperfectly risk-
adjusted outcomes may intentionally avoid very sick patients who are likely to have bad outcomes 
(Dranove et al., 2003); (3) Referral decisions by physicians may be influenced by non-clinical factors 
such as hospital affiliation, personal relationship, waiting time, etc (Lu and Lu, 2016).  Analyses of the 
impact of big data on precision medicine, as well as designs of pay-for-performance systems, must take 
behaviors like this into account.   
 
Finally, there are several important roles payers can play in the evolution of precision medicine. First, 
payers can help guide patients to the most suitable providers by structuring networks, co-pays and other 
policies to favor effective choices.  Second, by combining the above patient incentives with 
reimbursements that favor high quality outcomes, payers can influence providers to focus on patients and 
procedures that fit their relative strengths.  Third, payers can improve health care through pay-for-
performance that incent providers to invest in process improvements that result in better patient outcomes. 
The ability of payers to carry these out will depend critically on the analytics that underlie performance 
evaluation.    
 
5. Conclusion 
 
As depicted in Figure 3, the improved data collection and analysis that will result from the trends and 
activities discussed here will lead to stratified medicine that is increasingly better targeted at individual 
patient needs. Patients will use the improved information to make more informed decisions about their 
own health care, while providers will use it to make better strategic planning and process improvement 
decisions, and payers will use it to design better incentives for both patients and providers. The combined 
effect will be improved patient outcomes and greater efficiency due to elimination of waste and errors 
caused by trial-and-error medicine.  
 
  
 
Figure 3: Impact of Precision Medicine on Health Care Stakeholders. 
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For patients, the primary benefit of better decisions at all levels of the health care hierarchy will be better 
health. By providing evidence-based guidance to treatment options and provider choices that best suit an 
individual patient’s needs, precision medicine will lead to significant improvements in patient outcomes.  
Big data will amplify this impact by providing increasingly detailed evidence that increases the power and 
specificity of precision medicine.  
 
For example, a patient who suffers from severe depression today can expect it to take months, or even 
years, of consultation with psychiatrists, psychologists, therapists, yoga instructors, etc., to find a 
combination of medications and lifestyle changes that bring relief. In the coming world of precision 
medicine, the patient will receive treatments aligned with his/her individual characteristics and will see 
improvement much faster and will ultimately find a better health outcome.  
 
But patients will benefit from more than better health because of precision medicine. By shifting the basis 
for medical decisions away from subjective judgement and toward statistical evidence, big data will move 
the locus of decision-making toward patients. Under trial-and-error medicine, in which providers choose a 
course of action largely on their personal experience, a patient has little choice but to accept a 
recommendation based on the provider’s judgment. It’s not easy for a lay person to argue with an 
experienced medical professional who says, “in my considered opinion you should do X”. But under 
precision medicine, where there is an explicit base of evidence to indicate a course of action, it will 
become possible for the patient to argue with a recommendation without disparaging the recommender. 
For example, suppose an orthopedist recommended a total knee replacement based on data showing an 
80% chance of significant pain and mobility improvement and only a 5% chance of an outcome worse 
than the status quo. A particularly risk-averse patient could reasonably argue that the procedure is too 
risky for him/her. As data becomes more transparent, patients will become increasingly empowered to 
participate in more decisions regarding his/her health. The precision medicine revolution will ultimately 
bring about the end of paternalistic medicine. 
 
In addition to improving health outcomes at the individual and societal levels, precision medicine 
powered by big data will also reduce costs. Brownlee (2008) estimates that between one-fifth and one-
third of health care dollars are spent on unnecessary tests, drugs and treatments (and that such 
overtreatment is responsible for as many as 30,000 deaths per year). By providing a clear evidence base 
for determining which interventions are clinically worthwhile, big-data-driven precision medicine will 
help patients and providers avoid unnecessary treatments and their associated costs. Furthermore, by 
forgoing treatments that are not well-suited to the patient, precision medicine will lead to fewer errors, 
complications, and follow-up corrections, all of which will reduce costs. Finally, precision medicine can 
and should indicate where less invasive measures (e.g., prevention) are the best course of action. In the 
right situations, these approaches can achieve better health at dramatically reduced costs.   
 
The impact of the precision medicine revolution will impact provider behavior beyond interactions with 
patients. The detailed patient response data on which precision medicine is based will give clinicians and 
administrators granular feedback on their strengths and weaknesses. This will allow them to make 
strategic decisions about their focus, for example choosing which surgical procedures to offer or which 
patient types to target. It will also help them focus their process improvement efforts on the patients and 
services where improvements are most needed.  
 
Finally, precision medicine will open up a host of opportunities for payers to sharpen the incentives they 
provide to both patients and providers, with a goal of achieving better health outcomes at lower costs. 
When payers have detailed data on the best care options and choice of provider for a given patient, they 
can design pricing and co-payment schemes that incentivize patients to choose the most cost-effective 
alternatives. Similarly, they can design pay-for-performance reimbursement schemes that incentivize 
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payers to seek out patients where they have a comparative quality advantage and to invest in targeted 
process improvements.  
 
This impressive list of benefits will only be possible if we can resolve the data collection, estimation, 
modeling and optimization, and implementation issues discussed above. Since these are all challenges 
POM scholars are well-suited to address, the combined big data/precision medicine revolution is an area 
where our field can change the world for the better.  
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